The Cleveland Clinic Innovation Accelerator

克利夫兰诊所（CC）及其合作伙伴凯斯西储大学，辛辛那提儿童医院 医学中心，俄亥俄州州立大学和辛辛那提大学有一个长期的承诺， 在将实验室和临床创新转化为显著改善 患者护理，仅CC一家，通过其商业化部门CC创新（CCI），已经产生了53个分拆 在过去的十年中，CCI公司和6.44亿美元的股权融资;然而，CCI专注于更多 成熟的程序，并没有达到回到研究管道。此外，有助于商业化 申请机构的成功是建立了国家资助的全球心血管 创新中心（GCIC）的使命是推进心血管后期创新，即，“铲 有“快速创造就业机会的潜力”。申请人财团现在已经走到一起， 通过提出一个新的中心（克利夫兰临床创新加速器，CCIA）来解决未满足的需求， 总体目标是推动早期项目向前发展，教育研究人员成为全面合作伙伴， 将他们的发现转化为对病人护理有重大影响的进步。该中心将加强 并协调五个合作机构的现有资源，以推进非常强大的管道， 在NHLBI的使命区域（超过250个），每年都有实验室发现和技术创新 NHLBI资助的项目）。该申请有三个具体目标：（1）创建CCIA -一个自我维持的， 一个多机构联合体，致力于在NHLBI使命领域实现早期创新 转化为先进的解决方案，以改善全球患者护理。CCIA将通过以下方式补充GCIC的使命： 尽早进入发现和开发管道，以解决发现和开发之间的差距 研究和验证/临床前开发。(2)通过严格的同行评审， NHLBI资助的项目将获得资金和专家项目管理。项目应跨越 诊断、设备、治疗和工具的技术范围。(3)创建一个全国性的 生物医学创新领域的研究人员、临床医生和开发人员的教育和指导机构， 神秘主义。该中心将提供以经验为基础的培训，以培养一个不断增长的干部， 商业上成功的创新者。因此，CCIA的产生将创造一个自我可持续的引擎， 推动NHLBI相关研究发现的大量管道进入人类健康的进步。

Cleveland Clinic (CC) and its partners Case Western Reserve University, Cincinnati Children's Hospital Medical Center, The Ohio State University and University of Cincinnati have a longstanding commitment and documented success in transitioning laboratory and clinical innovations into dramatic improvements in patient care, CC alone, via its commercialization arm CC Innovations (CCI), has generated 53 spin-off companies and $644 million in equity financing in the past decade; however CCI has a focus on more mature programs and does not reach back into the research pipeline. Also, contributing to commercialization success of the applicant institutions has been the establishment of the state-funded Global Cardiovascular Innovation Center (GCIC) that has a mission of advancing late-stage cardiovascular innovations, i.e., "shovel ready" opportunities with rapid job creation potential. The applicant consortium has now come together to address an unmet need by proposing a new Center (Cleveland Clinic Innovation Accelerator, CCIA) with an overall goal of propelling early-stage projects forward and educating researchers to be full partners in transforming their discoveries into high-impact advances in patient care. The proposed Center will enhance and coordinate the existing resources of the five partnering institutions to advance the very strong pipeline of laboratory discoveries and technical innovations generated every year in NHLBI mission areas (over 250 NHLBI-funded projects). This application has three specifics aims: (1) To create the CCIA - a self-sustainable, multi-institutional consortium focused on translating early innovations in NHLBI mission areas into advanced solutions for improving global patient care. CCIA will complement the mission of the GCIC by reaching earlier into the discovery and development pipeline in order to address the gap between discovery research and validation/pre-clinical development. (2) To select through rigorous peer-review commercially-promising NHLBI funded projects that will receive funds and expert project management. Projects shall span the technology range of diagnostics, devices, therapeutics and tools. (3) To create a nationally accessible institute for educating and mentoring researchers, clinicians and developers in biomedical innovation and entrepreneurism. The Center will provide experience-based training to cultivate a growing cadre of commercially successful innovators. Generation of the CCIA will thus create a self-sustainable engine for propelling a large pipeline of NHLBI-related research discoveries into advances in human health.